Atossa Therapeutics (NASDAQ:ATOS - Get Free Report) was downgraded by investment analysts at StockNews.com from a "hold" rating to a "sell" rating in a research note issued to investors on Friday.
A number of other analysts also recently issued reports on ATOS. HC Wainwright reaffirmed a "buy" rating and set a $6.00 price target on shares of Atossa Therapeutics in a report on Thursday, October 31st. Ascendiant Capital Markets raised their price target on shares of Atossa Therapeutics from $6.25 to $6.50 and gave the company a "buy" rating in a report on Wednesday, September 11th.
Check Out Our Latest Analysis on Atossa Therapeutics
Atossa Therapeutics Price Performance
NASDAQ:ATOS remained flat at $1.50 on Friday. 548,309 shares of the company's stock were exchanged, compared to its average volume of 1,076,483. The firm has a market capitalization of $188.64 million, a P/E ratio of -7.14 and a beta of 1.23. Atossa Therapeutics has a 1-year low of $0.62 and a 1-year high of $2.31. The stock's 50 day moving average is $1.44 and its two-hundred day moving average is $1.38.
Atossa Therapeutics (NASDAQ:ATOS - Get Free Report) last released its quarterly earnings data on Monday, August 12th. The company reported ($0.05) earnings per share for the quarter, beating analysts' consensus estimates of ($0.06) by $0.01. As a group, research analysts predict that Atossa Therapeutics will post -0.22 EPS for the current fiscal year.
Hedge Funds Weigh In On Atossa Therapeutics
Several hedge funds have recently modified their holdings of the stock. XTX Topco Ltd purchased a new position in shares of Atossa Therapeutics in the second quarter worth $29,000. SG Americas Securities LLC raised its stake in Atossa Therapeutics by 254.3% during the third quarter. SG Americas Securities LLC now owns 41,849 shares of the company's stock valued at $64,000 after purchasing an additional 30,037 shares in the last quarter. Cetera Advisors LLC purchased a new stake in Atossa Therapeutics during the first quarter valued at $72,000. Vanguard Group Inc. raised its stake in Atossa Therapeutics by 1.4% during the first quarter. Vanguard Group Inc. now owns 5,753,993 shares of the company's stock valued at $10,357,000 after purchasing an additional 78,269 shares in the last quarter. Finally, Virtu Financial LLC purchased a new stake in Atossa Therapeutics during the first quarter valued at $151,000. Hedge funds and other institutional investors own 12.74% of the company's stock.
About Atossa Therapeutics
(
Get Free Report)
Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Atossa Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Atossa Therapeutics wasn't on the list.
While Atossa Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
